ES2155060T3 - Epitopos del virus de la hepatitis b incluidos en la respuesta de los linfocitos t citotoxicos (ctl) restringida para hla. - Google Patents

Epitopos del virus de la hepatitis b incluidos en la respuesta de los linfocitos t citotoxicos (ctl) restringida para hla.

Info

Publication number
ES2155060T3
ES2155060T3 ES92307764T ES92307764T ES2155060T3 ES 2155060 T3 ES2155060 T3 ES 2155060T3 ES 92307764 T ES92307764 T ES 92307764T ES 92307764 T ES92307764 T ES 92307764T ES 2155060 T3 ES2155060 T3 ES 2155060T3
Authority
ES
Spain
Prior art keywords
hbv
ctl
hla
restricted
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92307764T
Other languages
English (en)
Inventor
Maria A Vitiello
Robert W Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of ES2155060T3 publication Critical patent/ES2155060T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

PEPTIDOS ESTIMULANTES DEL LINFOCITO T CITOTOXICO QUE INDUCEN RESPUESTAS A LOS ANTIGENOS DEL VIRUS DE LA HEPATITIS B RESTRINGIDAS A LOS HLA. LOS PEPTIDOS, DERIVADOS DE LAS REGIONES EPITOPICAS DEL CTL TANTO DE LA SUPERFICIE DEL HBV COMO DE LOS ANTIGENOS NUCLEOCAPSIDOS, SON PARTICULARMENTE UTILES EN EL TRATAMIENTO Y PREVENCION DE LA INFECCION PROVOCADA POR EL HBV, INCLUIDO EL TRATAMIENTO DE PORTADORES DEL HBV INFECTADOS DE MANERA CRONICA. LOS PEPTIDOS SE PUEDEN FORMULAR COMO VACUNAS Y COMPOSICIONES FARMACEUTICAS CONTRA EL HBV, TALES COMO COMPOSICIONES QUE CONTENGAN LIPIDOS PARA INTENSIFICAR LAS RESPUESTAS DEL CTL RESTRINGIDAS A LOS HLA. LOS PEPTIDOS TAMBIEN SON UTILES EN METODOS DE DIAGNOSTICO, TALES COMO LA PREDICCION DE QUE INDIVIDUOS INFECTADOS CON EL HBV SON PROPENSOS A DESARROLLAR UNA INFECCION CRONICA.
ES92307764T 1991-08-26 1992-08-26 Epitopos del virus de la hepatitis b incluidos en la respuesta de los linfocitos t citotoxicos (ctl) restringida para hla. Expired - Lifetime ES2155060T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27

Publications (1)

Publication Number Publication Date
ES2155060T3 true ES2155060T3 (es) 2001-05-01

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92307764T Expired - Lifetime ES2155060T3 (es) 1991-08-26 1992-08-26 Epitopos del virus de la hepatitis b incluidos en la respuesta de los linfocitos t citotoxicos (ctl) restringida para hla.

Country Status (16)

Country Link
EP (2) EP1018344A3 (es)
JP (2) JP3738395B2 (es)
AU (1) AU687725B2 (es)
BG (1) BG98523A (es)
CA (1) CA2115839C (es)
CZ (1) CZ42794A3 (es)
DE (1) DE69231621T2 (es)
ES (1) ES2155060T3 (es)
FI (1) FI940918A7 (es)
GR (1) GR3035575T3 (es)
HU (1) HUT68510A (es)
IL (1) IL102964A0 (es)
NO (1) NO940660L (es)
NZ (2) NZ244103A (es)
OA (1) OA09888A (es)
WO (1) WO1993003764A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
BR9808529B1 (pt) * 1997-04-11 2010-10-05 oligopeptìdeo.
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2001036452A2 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs of class i epitodes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1740601B1 (en) * 2004-04-21 2012-12-05 The University of Chicago Myosin light chain kinase inhibitors and their use
JP2010500407A (ja) * 2006-08-14 2010-01-07 サイモン・エル・エル・シー Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
EP2687540A1 (en) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
KR102015648B1 (ko) 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ１ 펩티드 및 이를 포함한 백신
SG11201400432VA (en) * 2011-09-06 2014-08-28 Agency Science Tech & Res Polypeptide vaccine
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
US20140220056A1 (en) * 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
CA2840974A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
AU2016306527B2 (en) 2015-08-12 2022-03-17 Oncotherapy Science, Inc. DEPDC1-derived peptide and vaccine containing same
CA2995003A1 (en) * 2015-09-08 2017-03-16 Universitat Zurich Compositions against cat allergy
HK1251928A1 (en) 2015-10-08 2019-05-03 Oncotherapy Science, Inc. MPHOSPH1-derived peptides and vaccines including it
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments

Also Published As

Publication number Publication date
FI940918A0 (fi) 1994-02-25
NO940660L (no) 1994-04-22
JP3738395B2 (ja) 2006-01-25
BG98523A (en) 1995-05-31
HU9400581D0 (en) 1994-05-30
DE69231621D1 (de) 2001-02-08
NZ244103A (en) 1997-07-27
NO940660D0 (no) 1994-02-25
AU2548792A (en) 1993-03-16
CA2115839C (en) 2010-06-01
OA09888A (en) 1994-09-15
AU687725B2 (en) 1998-03-05
EP0534615A3 (en) 1994-05-25
CA2115839A1 (en) 1993-03-04
DE69231621T2 (de) 2001-05-31
WO1993003764A1 (en) 1993-03-04
GR3035575T3 (en) 2001-06-29
EP0534615A2 (en) 1993-03-31
JPH06510051A (ja) 1994-11-10
EP0534615B1 (en) 2001-01-03
FI940918L (fi) 1994-04-08
HUT68510A (en) 1995-06-28
EP1018344A2 (en) 2000-07-12
EP1018344A3 (en) 2000-09-20
JP3586278B2 (ja) 2004-11-10
JP2004075693A (ja) 2004-03-11
FI940918A7 (fi) 1994-04-08
CZ42794A3 (en) 1994-11-16
NZ270605A (en) 1997-07-27
IL102964A0 (en) 1993-01-31

Similar Documents

Publication Publication Date Title
Hotchin et al. Lymphocytic choriomeningitis infection of mice as a model for the study of latent virus infection
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
AU4203201A (en) Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
DK0610250T4 (da) Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ATE320444T1 (de) Peptide, die die zytotoxische t-lymphozyte antwort gegen hepatitis-b-virus induzieren
ES2141750T3 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
ES2164074T3 (es) Vacunas de virus de la hepatitis a.
ES2182847T3 (es) Nucleosidos y nucleotidos de anillo expandido.
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
RU2007115549A (ru) Вакцины на основе инактивированного цельного вируса совместимого субтипа для лечения пациентов с вич-инфекцией
Chang et al. Antigenic relationships of trachoma virus strains in the mouse toxicity prevention test
OA09672A (en) Use of il-4 to enhance immune response to infectious antigenic challenges
Jilg et al. Prolonged immunity after late booster doses of hepatitis B vaccine
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
ES2066206T3 (es) Utilizacion de adenilciclasa como vacunas contra bordetella.
Sypek et al. Antigen recognition by effector T cells in antileishmanial defense
ES2055610T3 (es) Vacuna contra hrsv.
ES2042481T1 (es) Peptidos sinteticos que derivan del antigeno hbc del virus de la hepatitis b.
Brinton et al. Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
MC2306A1 (fr) Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
FI803504L (fi) Vaccin och foerfarande foer dess framstaellning

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 534615

Country of ref document: ES